Gapping up
In reaction to earnings/guidance:
- BKE +2% (June comps)
Other news:
- VERU +11.4% (extends momentum from +13% move during regular session)
- ANVS +9.4% (received notice from the FDA that the Phase 3 clinical study in early Parkinson's patients may proceed)
- GME +6.7% (announces 4-for-1 stock split)
- BBBY +6% (interim CEO purchases 50000 shares)
- EGY +5.4% (completes South Tchibala 1HB-ST Well; provides operational update)
- CPG +5.2% (increases dividend)
- ATRA +4.9% (to announce completion of ATA188 Phase 2 EMBOLD Study interim analysis)
- AA +4.5% (Aloft Holdings in talks to acquire Portland Aluminum Smelter from AA according to The Australian)
- SGEN +4.4% (Merck (MRK) M&A talks advancing according to WSJ)
- SPCE +4.3% (chooses BA unit to design and manufacture next generation motherships)
- HITI +3.8% (acquires nine operating retail cannabis stores from Choom Holdings)
- CSIQ +3% (completes sale of two flagship solar farms in Australia)
- IREN +2.4% (Monthly Investor Update for June)
- NVMI +1.9% (announces that a leading analog and mixed-signal device maker recently adopted its VERAFLEX solution)
- HIVE +1.5% (provides June 2022 production update)
- WDFC +1.4% (names new CFO)
- RKLB +1.3% (introduces Responsive Space Program)
- GVA +1.3% (secures $55 mln for improvements to major Alaskan roadway)
- GILT +1.3% (awarded follow-on orders for the expansion of a defense force satellite communication (SATCOM) network in an Asian nation)
- SHEL +1.1% (provides Q2 update)
- ADTN +1.1% (Negotiations begin for domination agreement or a domination and profit and loss transfer agreement between Acorn HoldCo Inc. and ADVA Optical Networking SE)
- LLAP +1.1% (announced the successful deployment of the CAPSTONE spacecraft from a Rocket Lab Lunar Photon into a Lunar Transfer Orbit)
- ALKS +1% (Sarissa Capital affirms 8.55% active stake and previously disclosed annual meeting vote intentions)
Analyst comments:
- ADVM +4.1% (upgraded to Buy from Hold at Truist)
- CARE +1.4% (upgraded to Outperform from Mkt Perform at Raymond James)